Bio-Rad Laboratories, Inc. officer James Barry filed a Form 144 notice of proposed sale of 1,400 shares of Bio-Rad common stock, submitted on November 9, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services.

Key Highlights

  • Seller and role: James Barry, identified as an officer of Bio-Rad Laboratories, Inc., filed the notice.
  • Shares proposed for sale: 1,400 shares of common stock, with an aggregate market value of $539,876.82, according to the filing.
  • Shares outstanding: The filing reports 21,832,130 shares of common stock outstanding.
  • Approximate date of sale: November 9, 2026, on the NYSE.
  • Broker named: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
  • Acquisition history: The shares were acquired as restricted stock from the issuer on three separate dates: 156 shares on September 1, 2026; 658 shares on September 5, 2026; and 586 shares on September 6, 2026.
  • Prior sales: The filing reports nothing to disclose under securities sold during the past 3 months.

James Barry's Proposed Sale of Restricted Stock Shares at Bio-Rad Laboratories

According to the Form 144 filing, James Barry, an officer of Bio-Rad Laboratories, Inc. (NYSE:BIO), notified the Securities and Exchange Commission on November 9, 2026, of his intent to sell 1,400 shares of Bio-Rad common stock. The filing states the aggregate market value of the proposed sale is $539,876.82, and that the shares outstanding total 21,832,130.

The filing discloses that the 1,400 shares were acquired in three separate restricted stock transactions directly from the issuer. Specifically, 156 shares were acquired on September 1, 2026, 658 shares on September 5, 2026, and 586 shares on September 6, 2026. The nature of payment for all three acquisitions is listed as "Not Applicable" in the filing.

The filing further states that Barry "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed," as represented by his signature on the notice. No prior sales during the past three months were reported, and no Rule 10b5-1 trading plan details are noted in the filing.

What Was Disclosed

Bio-Rad Laboratories officer James Barry filed a Form 144 on November 9, 2026, disclosing a proposed sale of 1,400 shares of common stock with an aggregate market value of $539,876.82, acquired as restricted stock from the issuer in September 2026.